Denali Therapeutics (DNLI)
NASDAQ:DNLI
Holding DNLI?
Track your performance easily

Denali Therapeutics (DNLI) Financial Statements

624 Followers

Denali Therapeutics Financial Overview

Denali Therapeutics's market cap is currently ―. The company's EPS TTM is $-2.854; its P/E ratio is -9.41; Denali Therapeutics is scheduled to report earnings on October 31, 2024, and the estimated EPS forecast is $-0.60. See an overview of income statement, balance sheet, and cash flow financials.
Jun 24Dec 23Jun 23Mar 23Dec 22
Income Statement-
Total Revenue--$ 294.12M$ 35.14M-
Gross Profit--$ 294.12M$ 35.14M-
EBIT$ -116.59M$ -132.57M$ 183.38M$ 202.13M-
EBITDA$ -114.65M$ -130.40M$ 185.67M$ 212.18M-
Net Income Common Stockholders$ -99.03M$ -119.47M$ 183.38M$ 202.13M-
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 896.04M$ 1.03B$ 1.19B$ 1.29B$ 1.34B
Total Assets$ 1.50B$ 1.15B$ 1.31B$ 1.41B$ 1.46B
Total Debt$ 48.75M$ 44.98M$ 55.52M$ 57.09M$ 53.03M
Net Debt$ -847.29M$ -989.53M$ -1.14B$ -1.23B$ -1.28B
Total Liabilities$ 115.48M$ 122.96M$ 118.91M$ 442.64M$ 417.81M
Stockholders Equity$ 1.39B$ 1.03B$ 1.19B$ 966.71M$ 1.04B
Cash Flow-
Free Cash Flow$ -96.01M$ -100.89M$ -119.02M$ -61.59M-
Operating Cash Flow$ -91.22M$ -98.66M$ -113.17M$ -58.80M-
Investing Cash Flow$ 98.57M$ 73.05M$ 168.07M$ -92.72M-
Financing Cash Flow$ 6.76M$ 4.71M$ 9.02M$ 1.60M-
Currency in USD

Denali Therapeutics Earnings and Revenue History

Denali Therapeutics Debt to Assets

Denali Therapeutics Cash Flow

Denali Therapeutics Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis